The Experts below are selected from a list of 6630 Experts worldwide ranked by ideXlab platform
Arvind Chopra - One of the best experts on this subject based on the ideXlab platform.
-
Ayurvedic Medicine. Core concept, therapeutic principles, and current relevance.
The Medical clinics of North America, 2002Co-Authors: Arvind Chopra, Vijay V DoiphodeAbstract:In the prebiblical Ayurvedic origins, every creation inclusive of a human being is a model of the universe. In this model, the basic matter and the dynamic forces (Dosha) of the nature determine health and disease, and the medicinal value of any substance (plant and mineral). The Ayurvedic practices (chiefly that of diet, life style, and the Panchkarama) aim to maintain the Dosha equilibrium. Despite a holistic approach aimed to cure disease, therapy is customized to the individual's constitution (Prakruti). Numerous Ayurvedic Medicines (plant derived in particular) have been tested for their biological (especially immunomodulation) and clinical potential using modern ethnovalidation, and thereby setting an interface with modern Medicine. To understand Ayurvedic Medicine, it would be necessary to first understand the origin, basic concept and principles of Ayurveda.
-
Ayurvedic Medicine and arthritis
Rheumatic Diseases Clinics of North America, 2000Co-Authors: Arvind ChopraAbstract:The fundamental principles of Ayurveda are briefly reviewed. The ancient classification of arthritis is described along with the comparisons to the modern system. Though the diagnosis is historical and clinical, it is based on the tridosha hypothesis. The Ayurvedic pathogenesis links arthritis to the gut. Management chiefly consists of diet and lifestyle changes, the panchkarma process, and herbal drugs. The rasayana concept of immunomodulation is introduced. Clinical ethno-validation of the ancient therapy is necessary to meet the modern requirements and set up an interface with modern Medicine.
Masayuki Yoshikawa - One of the best experts on this subject based on the ideXlab platform.
-
On the structure of the bioactive constituent from Ayurvedic Medicine Salacia reticulata: revision of the literature
Tetrahedron Letters, 2008Co-Authors: Osamu Muraoka, Weijia Xie, Genzoh Tanabe, Mumen F. A. Amer, Toshie Minematsu, Masayuki YoshikawaAbstract:The reported structure of a potent α-glucosidase inhibitor 7 isolated recently from Ayurvedic Medicine Salacia reticulata was found incorrect, and the compound was proved to be de-O-sulfated kotalanol 4. Discussion and detailed analysis of the spectral data leading to the revised structure are presented.
-
Kotalanol, a Potent α-Glucosidase Inhibitor with Thiosugar Sulfonium Sulfate Structure, from Antidiabetic Ayurvedic Medicine Salacia reticulata
Chemical & pharmaceutical bulletin, 1998Co-Authors: Masayuki Yoshikawa, Toshiyuki Murakami, Kenichi Yashiro, Hisashi MatsudaAbstract:A potent natural α-glucosidase inhibitor called kotalanol has been isolated from an antidiabetic traditional Ayurvedic Medicine, the roots and stems of Salacia reticulata WIGHT, through bioassay-guided separation. The structure of kotalanol was elucidated on the basis of chemical and physicochemical evidence to be the inner salt comprised of 1-deoxyheptosyl-3-sulfate anion and 1-deoxy-4-thio-D-arabinofuranosyl sulfonium cation. Kotalanol was found to show more potent inhibitory activity against sucrase than salacinol and acarbose.
P Raviraj - One of the best experts on this subject based on the ideXlab platform.
-
The Cochrane Library - Ayurvedic Medicine for Schizophrenia
Cochrane Database of Systematic Reviews, 2011Co-Authors: V Agarwal, A Abhijnhan, P RavirajAbstract:Background Ayurvedic Medicine has been used to treat mental health problems since1000 BC. Objectives To review effects of Ayurvedic Medicine or treatments for schizophrenia. Search methods We searched the Cochrane Schizophrenia Group Trials Register (March 2007) and AMED (March 2007), inspected references of all identified studies and contacted the first author of each included study. Selection criteria We included all clinical randomised trials comparing Ayurvedic Medicine or treatments with placebo, typical or atypical antipsychotic drugs for schizophrenia and schizophrenia-like psychoses. Data collection and analysis We independently extracted data and calculated random effects, relative risk (RR), 95% confidence intervals (CI) and, where appropriate, numbers needed to treat/harm (NNT/H) on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD). Main results From the three small (total n=250) short included studies, we were unable to extract any data on many broad clinically important outcomes such as global state, use of services, and satisfaction with treatment. When Ayurvedic herbs were compared with placebo, about 20% of people left the studies early (n=120, 2 RCTs, RR 0.77 CI 0.37 to 1.62). Mental state ratings were mostly equivocal with the exception of the brahmyadiyoga group using Ayurvedic assessment (n=68, 1 RCT, RR not improved 0.56 CI 0.36 to 0.88, NNT 4 CI 3 to 12). Behaviour seemed unchanged (n=43, 1 RCT, WMD Fergus Falls Behaviour Rating 1.14 CI -1.63 to 3.91). Nausea and vomiting were common in the brahmyadiyoga group (n=43, RR 13.13 CI 0.80 to 216.30). When the Ayurvedic herbs were compared with antipsychotic drugs (chlorpromazine), again, equal numbers left the study early (n=120, 2 RCTs, RR for brahmyadiyoga 0.91 CI 0.42 to 1.97) but people allocated herbs were at greater risk of no improvement in mental state compared to those allocated chlorpromazine (n=45, RR 1.82 CI 1.11 to 2.98). Again, nausea and vomiting were found with use of brahmyadiyoga (n=45, 1 RCT, RR 20.45 CI 1.09 to 383.97, NNH 2 CI 2 to 38). Finally, when Ayurvedic treatment, in this case a complex mixture of many herbs, is compared with chlorpromazine in acutely ill people with schizophrenia, it is equally (˜10% attrition, n=36, RR 0.67 CI 0.13 to 3.53), but skewed data does seem to favour the chlorpromazine group. Authors' conclusions Ayurvedic medication may have some effects for treatment of schizophrenia, but has been evaluated only in a few small pioneering trials.
-
Ayurvedic Medicine for schizophrenia.
The Cochrane database of systematic reviews, 2007Co-Authors: V Agarwal, A Abhijnhan, P RavirajAbstract:Ayurvedic Medicine has been used to treat mental health problems since 1000 BC. To review effects of Ayurvedic Medicine or treatments for schizophrenia. We searched the Cochrane Schizophrenia Group Trials Register (March 2007) and AMED (March 2007), inspected references of all identified studies and contacted the first author of each included study. We included all clinical randomised trials comparing Ayurvedic Medicine or treatments with placebo, typical or atypical antipsychotic drugs for schizophrenia and schizophrenia-like psychoses. We independently extracted data and calculated random effects, relative risk (RR), 95% confidence intervals (CI) and, where appropriate, numbers needed to treat/harm (NNT/H) on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD). From the three small (total n=250) short included studies, we were unable to extract any data on many broad clinically important outcomes such as global state, use of services, and satisfaction with treatment. When Ayurvedic herbs were compared with placebo, about 20% of people left the studies early (n=120, 2 RCTs, RR 0.77 CI 0.37 to 1.62). Mental state ratings were mostly equivocal with the exception of the brahmyadiyoga group using Ayurvedic assessment (n=68, 1 RCT, RR not improved 0.56 CI 0.36 to 0.88, NNT 4 CI 3 to 12). Behaviour seemed unchanged (n=43, 1 RCT, WMD Fergus Falls Behaviour Rating 1.14 CI -1.63 to 3.91). Nausea and vomiting were common in the brahmyadiyoga group (n=43, RR 13.13 CI 0.80 to 216.30). When the Ayurvedic herbs were compared with antipsychotic drugs (chlorpromazine), again, equal numbers left the study early (n=120, 2 RCTs, RR for brahmyadiyoga 0.91 CI 0.42 to 1.97) but people allocated herbs were at greater risk of no improvement in mental state compared to those allocated chlorpromazine (n=45, RR 1.82 CI 1.11 to 2.98). Again, nausea and vomiting were found with use of brahmyadiyoga (n=45, 1 RCT, RR 20.45 CI 1.09 to 383.97, NNH 2 CI 2 to 38). Finally, when Ayurvedic treatment, in this case a complex mixture of many herbs, is compared with chlorpromazine in acutely ill people with schizophrenia, it is equally ( 10% attrition, n=36, RR 0.67 CI 0.13 to 3.53), but skewed data does seem to favour the chlorpromazine group. Ayurvedic medication may have some effects for treatment of schizophrenia, but has been evaluated only in a few small pioneering trials.
Sharon L. Kolasinski - One of the best experts on this subject based on the ideXlab platform.
-
Ayurvedic Medicine for Rheumatoid Arthritis
Current rheumatology reports, 2014Co-Authors: Shristi Basnyat, Sharon L. KolasinskiAbstract:Ayurvedic Medicine is the traditional Medicine of India, which originated over 5,000 years ago. Parts of this alternative medical system have become increasingly popular worldwide as patients seek approaches to medical care that they perceive as more holistic and less toxic than those offered by conventional Western Medicine. Despite the advent of highly effective pharmacologic therapy, most individuals with rheumatoid arthritis (RA) continue to use alternative therapy at some point in the treatment of their disease. This report discusses some of the in-vitro data that suggest potential mechanisms through which Ayurvedic herbal Medicines might have beneficial actions in rheumatoid arthritis, and the available clinical data evaluating the use of Ayurvedic Medicine for RA.
Edzard Ernst - One of the best experts on this subject based on the ideXlab platform.
-
Ayurvedic Medicine for rheumatoid arthritis: A systematic review
Seminars in arthritis and rheumatism, 2005Co-Authors: Jongbae Park, Edzard ErnstAbstract:OBJECTIVE To systematically review all randomized controlled trials (RCTs) on the effectiveness of Ayurvedic Medicine for rheumatoid arthritis (RA). METHODS Computerized literature searches for all RCTs of Ayurvedic Medicine for RA in the following databases: Medline (March 1969 to March 2003), Embase (February 1985 to February 2003), AMED (March 1980 to March 2003), Cochrane Controlled Trial Register (October 1997 to March 2003), and the abstract service of Central Council for Research in Ayurveda and Siddha (CCRAS; 1976 to March 2003). Hand searches were performed in 1 Sri Lankan and 3 Indian journals and the authors' personal files. Key data of included studies were extracted and reviewed. The methodological quality of all studies was evaluated with the Jadad scale. RESULTS Seven studies met our inclusion criteria. Trials tested either Ayurvedic Medicine against placebo or other Ayurvedic Medicines. In general, patient and physician global assessments on the severity of pain, and morning stiffness were used as endpoints. Of 3 placebo-controlled RCTs, 1 high-quality trial did not show benefit of the active treatment against placebo, while another incompletely reported study indicated beneficial effects of an Ayurvedic Medicine. A further incompletely reported study showed no significant difference. The remaining 4 trials were difficult to interpret because they tested an Ayurvedic Medicine against other Ayurvedic Medicines whose effects were not proven. CONCLUSION There is a paucity of RCTs of Ayurvedic Medicines for RA. The existing RCTs fail to show convincingly that such treatments are effective therapeutic options for RA.